Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30476580 | 1.00 | MMP2 (0.50) | MMP2ANPEPATMABCB1POLB | |
| SCHEMBL26615005 | 0.82 | MMP2 (0.36) | MMP2ANPEPPOLBL3MBTL1 | |
| SCHEMBL21111019 | 0.82 | MMP2 (0.36) | MMP2ANPEPPOLBL3MBTL1 | |
| SCHEMBL3032663 | 0.82 | ATM (0.53) | MMP2ANPEPATMABCB1POLB | |
| SCHEMBL18720347 | 0.82 | ATM (0.53) | MMP2ANPEPATMABCB1POLB | |
| SCHEMBL376608 | 0.82 | MMP2 (0.36) | MMP2ANPEPPOLBL3MBTL1 | |
| SCHEMBL3032665 | 0.82 | ATM (0.53) | MMP2ANPEPATMABCB1POLB | |
| Hydrochloric Acid SCHEMBL21682304 | 0.81 | MMP2 (0.35) | MMP2ANPEPPOLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL15265472 | 0.81 | MMP2 (0.35) | MMP2ANPEPPOLBL3MBTL1 | |
| SCHEMBL21702577 | 0.79 | MMP2 (0.38) | MMP2ANPEPATMPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118353-A1 | Medicinal composition | KITAJIMA AKIHIKO | 2009-05-07 | — | — | US | disclosed |
| US-7485665-B2 | Medicinal composition | NAGASE CHEMTEX CORPORATION (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20050239861-A1 | Medicinal composition | NAGASE CHEMTEX CORPORATION (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1547593-A1 | MEDICINAL COMPOSITION | Nagase Chemtex Corporation (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239861-A1 | Medicinal composition | HTR4, HTR2C, HTR1A | MMP2 160/4885ANPEP 1122/4885ATM 4070/4885 |
| US-20090118353-A1 | Medicinal composition | HTR4, FABP2, SLC10A2 | MMP2 117/4885ANPEP 924/4885ATM 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.